← All trials
NCT07211802
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2026
- Primary completion
- Jul 31, 2030
- Completion date
- Dec 31, 2030
- First posted
- Oct 8, 2025
- Last posted
- Oct 8, 2025
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- AbbottCollaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Institutes of Health (NIH)Collaborator
- Lexicon PharmaceuticalsCollaborator
- University of California, San DiegoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.